stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Free cash flow
Zymeworks Inc.'s free cash flow for fiscal 2025 was −$35.4M, compared with −$113.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$120.5M. Over the past ten years it has ranged from −$205.7M (fiscal 2021) to $131.0M (fiscal 2022); the current reading is higher than 64% of that period. Zymeworks Inc. ranks 474th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$35.4M | — |
| FY2024 | −$113.1M | — |
| FY2023 | −$122.4M | — |
| FY2022 | $131.0M | — |
| FY2021 | −$205.7M | — |
| FY2020 | −$157.7M | — |
| FY2019 | −$95.7M | — |
| FY2018 | $20.8M | — |
| FY2017 | −$2.9M | — |
| FY2016 | −$40.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$31.9M | — |
| Mar 2026 | −$45.9M | — |
| Dec 2025 | −$11.0M | — |
| Sep 2025 | −$31.8M | — |
| 39 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.0M |
| SEPN Septerna, Inc. compare | $117.6M |
| VCEL Vericel Corporation compare | $57.9M |
| COAG Hemab Therapeutics Holdings, Inc. compare | −$72.7M |
| ZYME Zymeworks Inc. | −$120.5M |
| IMNM Immunome, Inc. compare | −$219.1M |
| VERA Vera Therapeutics, Inc. compare | −$338.9M |
| BHVN Biohaven Ltd. compare | −$473.2M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$524.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement